Table 4

Impact of duration of treatment effect on treatment choice (threshold £30 000 per QALY gained)

SubgroupDuration of mortality treatment effectLifetime mortality and constant HRQoL
Lifetime7.5 years5 yearsMean f/up
Individuals without LBBB
 NYHA I, QRS <120 ms*ICDICDICDICDICD
 NYHA I, QRS ≥120 ms and <150 ms*ICDICDICDICDICD
 NYHA I, QRS ≥150 ms*CRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA II, QRS <120 msICDICDICDICDICD
 NYHA II, QRS ≥120 ms and <150 msICDICDICDICDICD
 NYHA II, QRS ≥150 msCRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA III, QRS <120 msICDICDICDMTICD
 NYHA III, QRS ≥120 ms and <150 msCRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA III, QRS ≥150 msCRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA IV, QRS <120 msMTMTMTMTMT
 NYHA IV, QRS ≥120 ms and <150 msCRT-PCRT-PCRT-PCRT-PCRT-P
 NYHA IV, QRS ≥150 msCRT-PCRT-PCRT-PCRT-PCRT-P
Individuals with LBBB
 NYHA I, QRS ≥120 ms and <150 ms*CRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA I, QRS ≥150 ms*CRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA II, QRS ≥120 ms and <150 msCRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA II, QRS ≥150 msCRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA III, QRS ≥120 ms and <150 msCRT-DCRT-DCRT-DCRT-DCRT-D
 NYHA III, QRS ≥150 msCRT-DCRT-DCRT-PCRT-PCRT-D
 NYHA IV, QRS ≥120 ms and <150 msCRT-PCRT-PCRT-PCRT-PCRT-P
 NYHA IV, QRS ≥150 msCRT-PCRT-PCRT-PCRT-PCRT-P
  • Changes from base case highlighted in bold.

  • *Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.

  • CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; HRQoL, health-related quality of life; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; MT, medical therapy; NYHA, New York Heart Association; QALY, quality-adjusted life-year.